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The publication of an epidemiological analysis in British physicians 1954 taught us thatsmoking is the main cause of lung cancer.1 It was a long way to get this message really
in the public and to reduce smoking behavior. Now-a-days in many parts of the world,
including the United States, programs for preventing the beginning of smoking, as well as
for the cessation of smoking, have been established. These programs lead to increased
awareness to the fact that about 10–15% of lung cancer cases (e.g. in the U.S.) arise in
life-long never-smokers.2 That means approximately 17,000–26,000 never-smokers in the
U.S. develop lung cancer annually.3 If we are looking at death rates, then in both smoking
and never-smoking men and women, the death rates of lung cancer are increasing
similarly with age.4 Therefore, the proportion of older and elderly patients is also in lung
cancer in never-smokers the most prominent one. Possible etiologies of lung cancer in
never-smokers are exposure to environmental tobacco smoke,5 occupational or environ-
mental exposure to other carcinogens (radon, cooking fumes, etc.), infection with human
papilloma virus 16/18, and an inherited susceptibility (germline mutations of EGFR,
polymorphisms of drug metabolizing enzymes). There seems to be a different biological
basis of carcinogenesis: never-smokers have a higher rate of EGFR-mutations in exons 19
and 21.6 On the other side K-ras mutations are rare in tumors of never-smokers and the
mutations in p53 differ. This leads to the hypothesis that there seems to be a smoking-
independent and a smoking-dependent carcinogenesis.
There have been reports that the outcome for never-smokers is better than that of
smokers.7,8 The retrospective analysis of Subramanian and colleagues9 of 254 life-long
never-smokers in this issue of the Journal confirms the preponderance of women (71.6%)
in this kind of lung cancer. The median age of the population in the study is 70 years; the
stage distribution is comparable between never-smokers and smokers. Regarding the
distribution of various histologies, they also find—as in previous studies—the survival
rates in the histological subtypes are 60.8% of adenocarcinoma and 13.6% of bronchio-
alveolar carcinoma, respectively. However, they do not find a better survival in the group
of patients with lung cancer in never-smokers. They matched 221 of these patients for
gender, histology, tumor stage, and years of diagnosis with smoking patients at the same
institution, then used a second control group and still found no statistically significant
difference in survival rates. The 5-year survival rate was 27.2% in never-smokers and
31.3% in smokers, respectively. Overall this study demonstrates that with valid statistical
analysis, the survival rate in never-smokers is not statistically different than that of
smokers. This is in contrast to earlier findings and reminds us that we need the correct
statistical design and hypothesis to get the correct answer. Of course confirmation of this
result is desirable, but also important is how to explain this result.
In summary, the simple question about the smoking status of lung-cancer patients
has helped us to detect the causal relationship between smoking and lung cancer and at the
least, stimulates the search for the biology of lung cancer in never-smokers. Cell and
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molecular biology are most important for the future of lung
cancer management, but simple figures can be used for
guidance.
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